ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1508

Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Abstract Number: 0898

Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Abstract Number: 0700

Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Abstract Number: 0687

Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Abstract Number: 1101

Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Abstract Number: 0759

Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Abstract Number: 0988

Distinct Effects of Inhibitory Receptor Agonism on RA Synovial CD4+ T Cell Functions
Abstract Number: 2129

Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses
Abstract Number: 0094

Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Abstract Number: 1831

Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Abstract Number: 1727

Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
Abstract Number: 1833

DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
Abstract Number: 0637

DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Abstract Number: 0625

DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Abstract Number: 0044

DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].